Gilead Marks Fifth Approval for Trodelvy^® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization

Gilead Sciences, Inc. announced that Health Canada has approved Trodelvy® for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior therapies, at least one of them for metastatic disease.